Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce its Preliminary Results for the twelve months ended 31st December, 2017 on Tuesday 6th March 2018.
Ali Mortazavi, Chief Executive Officer and David Ellam, Chief Financial Officer, will host a presentation for analysts at 9:00am on the day of the results at the Devonshire Club, 5 Devonshire Square, London EC2M 4YD.